Dr. Frances Shepherd CV - (NCRI) is

72. Patel A, Anraku M, Darling GE, Shepherd FA, Pierre Af, Waddell TK, Keshavjee S, de perrot
M. Venous thromboembolism in patients receiving multimodality therapy for thoracic
malignancies. J Thorac Cardiovasc Surg. 2009 Oct 138: 843-8.
73. Jang RW, Le Maitre A, Ding K, Winton T, Bezkjak A, Seymour L, Shepherd FA, Leighl NB.
Quality-adjusted time without symptoms of toxicity analysis of adjuvant chemotherapy in nonsmall
cell lung cancer: an analysis of the National Cancer Institute of Canada Clinical Trials
Group JBR.10 trial. J Clin Oncol. 2009; 27: 4268-73.
74. Leighl NB, Laurie SA, Chen XE, Ellis P, Shepherd FA, Knox JJ, Goss G, Burkes RL, pond GR,
Dick C, Yen Y, Zwiebel JA, moore MJ. A phase I/II study of GTI-2040 plus docetaxel as secondline
treatment in advanced non-small cell lung cancer; a study of the PMH phase II consortium. J
Thorac Oncol. 2009 Sep 4: 1163-9.
75. Hicks LK, Cheung MC, Ding K, Hasan B, Seymour L, Le Maitre A, Leighl NB, Shepherd FA.
Venous thromboembolism and non-small c ell lung cancer: a pooled analysis of the National
Cancer Institute if Canada clinical trials Group trials.Cancer. 2009 Dec 1: 5516-25.
76. Coate LE, John T, Taso MS, Shepherd FA. Molecular predictive and prognostic markers in nonsmall
cell lung cancer. Lancet Oncol. 2009 Oct 10: 1001-10.
77. Zhu CQ, Pintille M, John T, Strumpf D, Shepherd FA, Der SD, Jurisica I, Tsao MS.
Understanding prognostic gene expression signatures in lung cancer. Clin Lung Cancer. 2009;
10: 331-40.
78. Lara-Guerra H, Waddell TK, Salvarrey MA, Joshua AM, Chung CT, Paul N, Boerner S, Sakurada A,
Ludkovski O, Ma C, Squire J, Liu G, Shepherd FA, Taso MS, Leighl NB. Phase II Study of
Perioperative Gefitinib in Clinical Stage I Non-Small Cell Lung Cancer. J Clin Oncol. 2009; 27:
6229-36
79. Goss GD, Arnold A, Shepherd FA, Dediu M, Ciuleanu TE, Fenton D, Zukin M, Walde D,
Laberge F, Vincent MD, Ellis PM, Laurie SA, Ding K, Frymire E, Gauthier I, Leighl NB, Ho C,
Noble J, Lee CW, Seymour L. Randomized, Double-blind trial of Carboplatin abd Paclitaxel With
Either Daily Oral Cediranib or Placebo in Advanced Non-Small Cell Lung Cancer: NCIC Clinical
trials Group BR.24 Study. J Clin Oncol. 2010; 28: 49-55.
80. Douillard JY, Shepherd FA, Hirsch V, Mok T, Socinski MA, Gervais R, Liao ML, Bischoff H,
Reck M, Sellers MV, Watkins CL, Speake G, Armour AA, Kim ES. Molecular Predictors of
Outcome with gefitinib and docetaxel in Previously Treated Non-Small Cell Lung Cancer: Data
from the Randomized Phase III INTEREST Trial. J Clin Oncol. 2010; 28: 44-52.
81. Douillard JY, Tribodet H, Aubert D, Shepherd FA, Rosell R, Ding K, Veillard AS, Seymour L,
Le Chevalier T, Spiro S, Stephens R, Pignon JP, LACE Collaborative Group. Adjuvant cisplatin
and vinorelbine for completely resected non-small cell lung cancer: subgroup analysis of Lung
Adjuvant Cisplatin Evaluation. J Thoracic Oncol. 2010; 5: 220-8.
82. Wheatley-Price P, Ma C, Ashcroft LF, Nankivell M, Stephens RJ, White SC, Lorigan P, Thatcher
N, Blackhall FH, Shepherd FA. The Strength of female sex as a prognostic factor in small-cell
lung cancer: a pooled analysis of chemotherapy trials from the Manchester Lung Group and
medical research Council Clinical Trials Unit. Ann Oncol. 2010; 21: 232-7.
83. Bradbury PA, Tu D, Seymour L, Isogai PK, Zhu L, Ng R, Mittman N, Tsao MS, Evans WK,
Shepherd FA, Leighl NB, NCIC Clinical Trials Group Working Group on Economic Analysis.
Economic Analysis: randomized placebo-controlled clinical trials of erlotinib in advanced nonsmall
cell lung cancer. J Natl Cancer Inst. 2010; 102: 298-306.
84. Ross HJ, Blumenschein GR Jr, Aisner J, Damjanov N, Dowlati A, Garst J, rigas JR, Smylie M,
Hassani H, Allen KE, Leopold L, Zaks TZ, Shepherd FA. Randomized phase II multicenter trial
of two schedules of lapatinib as first or second-line monotherapy in patients with advanced or
metastatic non-small cell lung cancer. Clin Cancer Res 2010; 16: 1938-49.
85. Wheatley-Price P, Blackhall F, Lee SM, Ma C, Ashcroft L Jitlal M, Qian W, Hackshaw A, Rudd
R, Booton R, Danson S, Lorigan P, Thatcher N, Shepherd FA. The influence of sex and
11